<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573715</url>
  </required_header>
  <id_info>
    <org_study_id>2011-005720-18</org_study_id>
    <secondary_id>2011-39</secondary_id>
    <nct_id>NCT01573715</nct_id>
  </id_info>
  <brief_title>Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS)</brief_title>
  <official_title>Effects of NMBA on the Alteration of Transpulmonary Pressures at the Early Phase of ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mortality in Acute Respiratory Distress Syndrome is high (40 to 60 %). Protective mechanical
      ventilation, until 2010, was the cornerstone of the ARDS therapeutic strategies. Recently, a
      prospective multicenter study demonstrates that a 48h continuous infusion of neuromuscular
      blocking agents (NMBA) have a positive impact on mortality of ARDS patients. (Papazian et al.
      ACURASYS Study. NEJM 2010; 363:1107-16). The mechanisms through which NMBAs could improve
      survival remain speculative. They are as follows:

        -  reduction of the consumption of oxygen linked to ventilatory workload;

        -  increase of chest wall compliance improving mechanical ventilation during ARDS and
           better adaptation to the protective ventilation strategy;

        -  anti-inﬂammatory effect contributing to a reduction in pulmonary inﬂammation and
           improvement in oxygenation,

        -  reduction of the variations of transpulmonary pressure (TPP) by the way of better
           synchronisation between patient and the ventilator.

      The use of NMBA could also reduce the ventilator induced lung injury by a better control of
      TPP.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta TPP</measure>
    <time_frame>27 months</time_frame>
    <description>Reduction of Delta TPP at 48 hr in the NMBA group by comparison with the control group in ARDS patients</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>severe ARDS patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate SDRA patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIMBEX</intervention_name>
    <arm_group_label>severe ARDS patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIMBEX</intervention_name>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>moderate SDRA patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>WITHOUT NIMBEX</intervention_name>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>moderate SDRA patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Early (&lt; 48H) Severe ARDS: PaO2 / FiO2 ratio &lt; 150 with PEEP &gt;= 5 cmH20

        Exclusion Criteria:

        Age &lt; 18 ans Patient already under continuous infusion NMBA. Known NMBA Allergy or
        intolerance Contra-indication to introduction of nasogastric tube
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BERNARD BELAIGUES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>magali BISBAL</last_name>
    <email>magali.bisbal@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>magali BISBAL</last_name>
      <email>magali.bisbal@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>magali BISBAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2012</study_first_posted>
  <last_update_submitted>August 29, 2014</last_update_submitted>
  <last_update_submitted_qc>August 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromuscular Blocking Agents</mesh_term>
    <mesh_term>Cisatracurium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

